Dongwha Pharm동화약품
000020 · KOSPI · ₩000020 · 동화약품
₩5,100▼ ₩60 (1.16%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩496B | ₩465B | ₩361B | ₩340B | ₩293B |
| Cost of sales | ₩278B | ₩251B | ₩171B | ₩159B | ₩144B |
| Gross profit | ₩219B | ₩214B | ₩190B | ₩181B | ₩149B |
| Operating income | ₩257M | ₩13B | ₩19B | ₩30B | ₩22B |
| Net income | ₩3.8B | ₩2.1B | ₩28B | ₩22B | ₩20B |
| Net income to shareholders | ₩8.7B | ₩5.6B | ₩27B | ₩20B | ₩18B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩642B | ₩620B | ₩565B | ₩461B | ₩448B |
| Current assets | ₩218B | ₩238B | ₩238B | ₩228B | ₩220B |
| Cash and equivalents | ₩13B | ₩26B | ₩72B | ₩34B | ₩60B |
| Total liabilities | ₩241B | ₩218B | ₩158B | ₩82B | ₩88B |
| Current liabilities | ₩203B | ₩134B | ₩106B | ₩76B | ₩66B |
| Borrowings | ₩102B | ₩76B | ₩31B | ₩3B | ₩8B |
| Total equity | ₩401B | ₩402B | ₩407B | ₩379B | ₩360B |
| Shareholders' equity | ₩380B | ₩373B | ₩372B | ₩364B | ₩347B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩16B | −₩4B | ₩29B | ₩29B | ₩36B |
| Capital spending | ₩53B | ₩37B | ₩25B | ₩18B | ₩22B |
| Free cash flow | −₩37B | −₩41B | ₩4.6B | ₩11B | ₩14B |
| Dividends paid | ₩5B | ₩5B | ₩5B | ₩5B | ₩5B |
Consolidated where available. Amounts in won.
Also known as: Dongwha Pharm / 동화약품 / 000020 / KRX:000020
Source: KRX statistical information